Boulder, CO – According to filings with the U.S. Securities and Exchange Commission, ArcherDX is raising $55,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Jason Myers played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About ArcherDX

ArcherDX, Inc., creates catalog and custom next-generation sequencing (NGS) assays that are purpose-built to identify mutations and gene fusions from clinical sample types. By combining novel enrichment chemistry, automated informatics and a user-friendly workflow, Archer products remove the bottlenecks associated with using next-gen sequencing in a translational setting.

To learn more about ArcherDX, visit http://archerdx.com/

Contact:
Jason Myers, Chief Executive Officer
877-771-1093
jmyers@archerdx.com
https://www.linkedin.com/in/jason-myers-88912113/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved